Multiple myeloma

被引:674
作者
Raab, Marc S. [1 ,2 ,3 ,4 ,5 ]
Podar, Klaus [1 ,2 ]
Breitkreutz, Iris [1 ,2 ,4 ,5 ]
Richardson, Paul G. [1 ,2 ]
Anderson, Kenneth C. [1 ,2 ]
机构
[1] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA
[3] Heidelberg Univ, Med Ctr, Dept Med 5, Heidelberg, Germany
[4] Natl Ctr Tumor Dis, Heidelberg, Germany
[5] German Canc Res Ctr, D-6900 Heidelberg, Germany
关键词
STEM-CELL TRANSPLANTATION; THALIDOMIDE PLUS DEXAMETHASONE; HIGH-DOSE THERAPY; PEGYLATED LIPOSOMAL DOXORUBICIN; PROTEASOME INHIBITOR BORTEZOMIB; BONE-MARROW-TRANSPLANTATION; PREVIOUSLY TREATED PATIENTS; MONOCLONAL GAMMOPATHY; HIGH-RISK; ELDERLY-PATIENTS;
D O I
10.1016/S0140-6736(09)60221-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma is characterised by clonal proliferation of malignant plasma cells, and mounting evidence indicates that the bone marrow microenvironment of tumour cells has a pivotal role in myeloma pathogenesis. This knowledge has already expanded treatment options for patients with multiple myeloma. Prototypic drugs thalidomide, bortezomib, and lenalidomide have each been approved for the treatment of this disease by targeting both multiple myeloma cells and the bone marrow microenvironment. Although benefit was first shown in relapsed and refractory disease, improved overall response, duration of response, and progression-free and overall survival can be achieved when these drugs are part of first-line regimens. This treatment framework promises to improve outcome not only for patients with multiple myeloma, but also with other haematological malignancies and solid tumours.
引用
收藏
页码:324 / 339
页数:16
相关论文
共 150 条
[11]   Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome [J].
Avet-Loiseau, Herve ;
Attal, Michel ;
Moreau, Philippe ;
Charbonnel, Catherine ;
Garban, Frederic ;
Hulin, Cyrille ;
Leyvraz, Serge ;
Michallet, Mauricette ;
Yakoub-Agha, Ibrahim ;
Garderet, Laurent ;
Marit, Gerald ;
Michaux, Lucienne ;
Voillat, Laurent ;
Renaud, Marc ;
Grosbois, Bernard ;
Guillerm, Gaelle ;
Benboubker, Lotfi ;
Monconduit, Mathieu ;
Thieblemont, Catherine ;
Casassus, Philippe ;
Caillot, Denis ;
Stoppa, Anne-Marie ;
Sotto, Jean-Jacques ;
Wetterwald, Marc ;
Dumontet, Charles ;
Fuzibet, Jean-Gabriel ;
Azais, Isabelle ;
Dorvaux, Veronique ;
Zandecki, Marc ;
Bataille, Regis ;
Minvielle, Stephane ;
Harousseau, Jean-Luc ;
Facon, Thierry ;
Mathiot, Claire .
BLOOD, 2007, 109 (08) :3489-3495
[12]   Lenalidomide overcomes poor prognosis conferred by deletion of chromosome 13 and t(4;14) in multiple myeloma: MM016 trial. [J].
Bahlis, Nizar J. ;
Mansoor, Adnan ;
Lategan, Johannes C. ;
Valentine, Karen ;
Thaell, Tedd ;
Blahey, Walter ;
Savoie, Mary Lynn ;
Blaikie, Kim ;
Kmet, Leanne ;
Roland, Birgitte ;
Stewart, Douglas A. .
BLOOD, 2006, 108 (11) :1016A-1016A
[13]  
BARLOGIE B, 1987, BLOOD, V70, P869
[14]   Total therapy with tandem transplants for newly diagnosed multiple myeloma [J].
Barlogie, B ;
Jagannath, S ;
Desikan, KR ;
Mattox, S ;
Vesole, D ;
Siegel, D ;
Tricot, G ;
Munshi, N ;
Fassas, A ;
Singhal, S ;
Mehta, J ;
Anaissie, E ;
Dhodapkar, D ;
Naucke, S ;
Cromer, J ;
Sawyer, J ;
Epstein, J ;
Spoon, D ;
Ayers, D ;
Cheson, B ;
Crowley, J .
BLOOD, 1999, 93 (01) :55-65
[15]   Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].
Barlogie, B ;
Tricot, G ;
Anaissie, E ;
Shaughnessy, J ;
Rasmussen, E ;
van Rhee, F ;
Fassas, A ;
Zangari, M ;
Hollmig, K ;
Pineda-Roman, M ;
Lee, C ;
Talamo, G ;
Thertulien, R ;
Kiwan, E ;
Krishna, S ;
Fox, M ;
Crowley, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030
[16]   Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients [J].
Barlogie, B ;
Desikan, R ;
Eddlemon, P ;
Spencer, T ;
Zeldis, J ;
Munshi, N ;
Badros, A ;
Zangari, M ;
Anaissie, E ;
Epstein, J ;
Shaughnessy, J ;
Ayers, D ;
Spoon, D ;
Tricot, G .
BLOOD, 2001, 98 (02) :492-494
[17]   EFFECTIVE TREATMENT OF ADVANCED MULTIPLE-MYELOMA REFRACTORY TO ALKYLATING-AGENTS [J].
BARLOGIE, B ;
SMITH, L ;
ALEXANIAN, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1984, 310 (21) :1353-1356
[18]  
BARLOGIE B, 2008, P AN M AM SOC CLIN, V26, P8516
[19]   Myeloma bone disease [J].
Berenson, JR .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (04) :653-672
[20]   Molecular pathogenesis and a consequent classification of multiple myeloma [J].
Bergsagel, PL ;
Kuehl, WM .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (26) :6333-6338